NASDAQ:LSTA Lisata Therapeutics - LSTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.67 +0.01 (+0.27%) (As of 02/7/2023 02:47 PM ET) Add Compare Share Share Today's Range$3.63▼$3.7150-Day Range$2.39▼$3.7552-Week Range$2.36▼$12.30Volume8,361 shsAverage Volume15,446 shsMarket Capitalization$28.85 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Lisata Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside304.3% Upside$15.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.09) to ($3.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector426th out of 1,029 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry6th out of 9 stocks 3.5 Analyst's Opinion Consensus RatingLisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Lisata Therapeutics has a forecasted upside of 304.3% from its current price of $3.71.Amount of Analyst CoverageLisata Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LSTA. Previous Next 0.0 Dividend Strength Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LSTA. Previous Next 4.1 News and Social Media Coverage News SentimentLisata Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lisata Therapeutics this week, compared to 0 articles on an average week.Search Interest4 people have searched for LSTA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Lisata Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 6.00% of the stock of Lisata Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($8.09) to ($3.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lisata Therapeutics (NASDAQ:LSTA) StockLisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.Read More Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LSTA Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comLisata Therapeutics Announces Participation in Upcoming Conferences in FebruaryJanuary 9, 2023 | technews.tmcnet.comRactigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating OfficerFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 9, 2023 | finance.yahoo.comLisata Therapeutics, Inc. (LSTA)November 13, 2022 | seekingalpha.comLisata Therapeutics, Inc. (LSTA) Q3 2022 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comLisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 7, 2022 | finance.yahoo.comLisata Therapeutics Announces Participation in Upcoming Conferences in November 2022November 3, 2022 | finance.yahoo.comLisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern TimeFebruary 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.October 27, 2022 | seekingalpha.comLSTA Lisata Therapeutics, Inc.October 21, 2022 | reuters.comLisata Therapeutics IncOctober 19, 2022 | finance.yahoo.comLisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research AwardOctober 19, 2022 | finance.yahoo.comLisata Therapeutics Announces Participation in Upcoming Conferences in October 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LSTA Company Calendar Last Earnings11/10/2022Today2/07/2023Next Earnings (Estimated)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LSTA CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+308.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($12.2279) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.53% Return on Assets-27.96% Debt Debt-to-Equity RatioN/A Current Ratio12.09 Quick Ratio12.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$23.07 per share Price / Book0.16Miscellaneous Outstanding Shares7,860,000Free Float7,687,000Market Cap$28.85 million OptionableNot Optionable Beta1.10 Key ExecutivesDavid J. MazzoChief Executive Officer & DirectorDavid SlackPresident, Director & Chief Business OfficerJames NiscoVice President-Finance & TreasuryGregory S. BerkinChief Information OfficerKristen K. BuckChief Medical OfficerKey CompetitorsOntrakNASDAQ:OTRKGreenbrook TMSNASDAQ:GBNHEdesa BiotechNASDAQ:EDSAVapothermNYSE:VAPOZynerba PharmaceuticalsNASDAQ:ZYNEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 176,305 shares on 11/15/2022Ownership: 4.363%BlackRock Inc.Bought 56,807 shares on 11/15/2022Ownership: 1.406%State Street CorpBought 14,349 shares on 11/15/2022Ownership: 0.355%Renaissance Technologies LLCBought 100,922 shares on 11/14/2022Ownership: 2.497%Dimensional Fund Advisors LPBought 12,333 shares on 11/10/2022Ownership: 0.305%View All Institutional Transactions LSTA Stock - Frequently Asked Questions Should I buy or sell Lisata Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LSTA shares. View LSTA analyst ratings or view top-rated stocks. What is Lisata Therapeutics' stock price forecast for 2023? 2 brokerages have issued 12-month price objectives for Lisata Therapeutics' shares. Their LSTA share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 304.3% from the stock's current price. View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts. How have LSTA shares performed in 2023? Lisata Therapeutics' stock was trading at $2.53 on January 1st, 2023. Since then, LSTA shares have increased by 46.6% and is now trading at $3.71. View the best growth stocks for 2023 here. When is Lisata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our LSTA earnings forecast. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.58. What is Lisata Therapeutics' stock symbol? Lisata Therapeutics trades on the NASDAQ under the ticker symbol "LSTA." Who are Lisata Therapeutics' major shareholders? Lisata Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lisata Therapeutics' stock price today? One share of LSTA stock can currently be purchased for approximately $3.71. How much money does Lisata Therapeutics make? Lisata Therapeutics (NASDAQ:LSTA) has a market capitalization of $29.16 million. The company earns $-27,470,000.00 in net income (profit) each year or ($12.2279) on an earnings per share basis. How can I contact Lisata Therapeutics? Lisata Therapeutics' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The official website for the company is www.caladrius.com. The company can be reached via phone at (908) 842-0100, via email at jmenditto@caladrius.com, or via fax at 646-514-7787. This page (NASDAQ:LSTA) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.